Assessment of Biomarkers in Patients Co-Infected with HIV/HBV Attending the Antiretroviral Clinic in a Tertiary Institution
International Journal of TROPICAL DISEASE & Health,
Aim: The level of some biomarkers such as the Lipid profiles and some liver enzymes were checked for in patients who were found to be co infected with HIV/HBV
Study Design: The study was conducted among patients infected with the Human Immunodeficiency Virus attending the antiretroviral clinic at the Braith Waite memorial hospital, Port Harcourt, Rivers State. The samples and relevant data were gotten between the months of January and March 2019, using a structured questionnaire
Methodology: The Samples were collected from patients infected with HIV attending the Braith Waite memorial hospital on antiretroviral medication. A total number of 98 samples were collected and analyzed for the presence of HBV IgM core antibody using the ELISA method. The statistical analysis was done using a Stata version 16 and the student T-test was used to determine the P value. A total of 98 samples were collected, 66(67.3%) were females and 32(32.6%) of them were males. Of the 98 samples, 5 (5.1%) of them were positive to HIV/HBV co infection of which 3(3.1%) were females and 2(2%) were males. The age range for those co infected was between 29 – 34 years old. The lipid profile and liver enzymes for the positive samples were analyzed. The result showed an increase in the level of LDL, HDL and triglyceride. The analysis for the liver enzymes showed an increase in the level of AST and ALP while the ALT and GGT remained within the healthy range. The increase in the level of most of the biomarkers, showed that the patients co infected with HIV/HBV were at risk of heart and kidney diseases since they are already immunocompromised. From this result, it shows that patients who are HIV positive should undergo HBV test regularly. Those who are positive should have their biomarkers monitored and put under medication early.
- Hepatitis B virus
- human immunodeficiency virus
- liver enzymes
- lipid profiles
How to Cite
Schweitzer A, Horn J, Mikolajcyk RT, et al. Estimations of Worldwide prevalence of chronic hepatitis B virus infection a systematic review of data published between 1965 and 2013 Lancet. 2015;386(10003):1546-55.
Thio CL, Seaberg EC, Skolasky R Jr., Phair J, Visscher B, Munoz A, Thomas DL, Multicenter ACS.. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921-6.
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V 3rd, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R. North American ACCoR, Design of Ie DEA, North American ACCoR, Design of Ie DEA. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Co-infected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin Infect Dis. 2016;63(9):1160-7.
Singh KP, Crane M, Audsley J, Lewin SR. HIV-Hepatitis B virus co-infection: epidemiology, pathogenesis and treatment. AIDS. 2017; 31(15): 2035–2052.
Loomba R, Liang TJ. Treatment of Hepatitis B. Antivir Ther.2007;12Suppl3:H33-41.PMID:18284181.
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. ‘’A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010’’. Lancet. 2012;380:2224–60
Pouti M, Bruno R, Soriano V. Donato FM Gaeta GB, Quizan GP, Precone D, Gellati U, Aseni V, Vaccher ;HIV HCC Cooperative Italian-Spanish group. Hepatocellular carcinoma in HIV- infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18(17):2285–2293.
Thomas RB. An Energy-Restricted, Low Glycemic Index Diet with Omega-3 Fatty Acid and Vitamin D3 Supplementation in Adults with Metabolic Syndrome. Guelph, ON, Canada: The University of Guelph. 2012;54–8.
Katsuramaki T, Mizuguchi T, Nagayama M, Kimura Y, Furuhata T, Yamaguchi K, et al. Analysis of the changes pattern of serum apolipoprotein A-1 after hepatectomy. Hepatogastroenterology. 2006;53(72):924–927
Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, Kratky D, Sattler W, Reicher H, Sinner F, Gumhold J, Silber D, Fauler G, Hofler G,Lass A, Zechner R,Trauner M. (2012). Alteration in Lipid Metabolism mediated Inflamation, Fibrosis and Proliferation in a Mouse Model of Chronic Cholestatic Liver Injury. Original Research Basic and Translational Liver. 2012;142(1):140-151.
EasL Clinical Practice Guidelines. Management of Cholestasis liver Disease. J. Hepatol. 2009;51(2):237-67 [PubMed][Google Scholar].
Chauvel O, Lacombe K, Bonnard P, Lascoux-Combe C, Molina J, Mialhes P, Girard P, Carrat F. Risk factors for acute liver enzyme abnormalities in HIV – hepatitis B virus co infected patients on antiretroviral therapy. Antiviral Therapy. 2007;12:1115 – 1126.
Whitehead MW,Hawkes ND,Hainsworth I,Kingham JG. A prospective study of notably raised aspartate aminotransferase of liver origin. Gut.1999;45:129-133.
Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008;118:2047–2056.
Szternel L, Krintus M, Bermann K, Derezinski T, Sypniewska G. Non Fasting Lipid Profile Determination in Presumably Healthy Children: Impact on the assessment of the lipid abnormalities. PLoS One. 2018;13(6): e019843.s
Okonko IO, Horsefall SJ, Okerentuba PO, Frank Peterside N. HBV and HIV co infection among intending donors in Port Harcourt, Nigeria. J. Immunoassay Immunochemistry. 2015;36 (4):359-67.
Anigilaje AE, Olutola A. Prevalence and Clinical and Immunoviralogical Profile of Human Immunodeficiency Virus-Hepatitis B Coinfection among Children in an Antiretroviral Therapy Programme in Benue State, Nigeria. International Scholarly Research Notices, 2013;2013;7. Article ID 932697.
Kye-Duodu G, Nortey P, Malm K, Nyarko KM, Sackey SO, Ofori S, Afari EA. Prevalence of hepatitis B virus co-infection among HIV-seropositive persons attending antiretroviral clinics in the Eastern Region of Ghana. Pan African Medical Journal. 2016;25(1):7.
Lawal MA, Adeniyi OF, Akintan PE, Salako AO, Omotosho OS, Temiye EO. Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria. PLoS One. 2020;15(12).
Nyirenda M, Beadsworth MBJ, Stephany P, Hart CA, Hart IJ, Munthali C et al. Prevalence of infection with hepatitis B and C virus and co infection with HIV in medical inpatients in Malawi. J Infect. 2008;57(1):72-7.
Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, Fraune M et al. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol. 2010;48(9):3223-30
Nwolisa E, Mbanefo F, Ezeogu J, Amadi P. Prevalence of Hepatitis B co infection amongst HIV infected children attendin a care and treatment center in Owerri, south eastern Nigeria. Pan African Medical Journal.2013;14:89.
Boateng R, Mutochelu M, Dompreh A, Obiri-Yeboah D, Odame Anto E, Owusu M, et al. Sero prevalence of Hepatitis B and C co infection among HIV-1 infected ART naïve individuals in Kumasi Ghana. PLoS One. 2019;14(4): e0215377.
Marceline DJ, Cyriaque AA, Ida Marlene GT, Paul MF. Human Immunodeficiency Virus and Hepatitis B virus(HIV/HBV) co infection in people living with HIV/AIDS identified in Yaounde central Hospital Cameroon:Seroprevalence and impact on the disease progression. academicJournals. 2017;9(6):123 – 128.
Pakhale MR, Ramteke T, Tadas A. Change in lipid profile and liver enzymes in HIV infection and AIDS patients. International Journal of scientific research publications. 2015;5(9) 2015:2250 -3153.
Nayyar AS. Dislipidemia in HIV infected and AIDS patients: Association of serum lipid with HIV status, across sectional study. Journal of Medicine in the Tropics. 2019;21(1):20 – 25.
Arain SQ, Talpur FN, Channa NA. Serum ipid profile as a marker of liver impairment in hepatitis B cirrhosis patients. Lipid Health Dis. 2017 ;16:51.
Quaye O, Amuzu BG, Adodey SM, Tagoe EA. Effect of hepatitis B virus (HBV) on lipid profile in Ghana patients. Virology(Aukl) 2019;10:1178122X19827606.
Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3:269–282
Amirzadegan A, Salarifar M, Sadeghian s et al.,Correlation between ABO blood groups, major risk factors and coronary artery disease. Int J Cadiol. 2006;110:256 – 258.
Wright RS, Murphy JG. Mitiating Risk Patients with Dyslipidemia: A Statin A Day Does Not Always Keep The Doctor Away In Those With Elevated Triglycerides.J. MayoCP. 2019;94(9):1659 -1661.
Adewole OO, Anteyi E, Ajuwon Z, Wada I, Elegba F, Ahmed P, Betiku Y, Okpe A, Eze S, Ogbeche T, Erhabor GE. Hepatitis B virus; hepatitis C virus; Human immunodeficiency virus; Risk factors, presentation. J Infect Dev Ctries. 2009; 3(5):369-375.
Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev. 2002;4:27–35.
Malakouti M, Kataria A, Ali SK, Schenker S. Elevated Liver Enzymes In Asymptomatic Patients – What Should I Do?’’ J Clin Transl Hepatol;2017.
Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112 :18–35.
Giannini E, Botta F, Testa E, Romagnoli P, Polegato S, Malfatti F, et al. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. Am J Gastroenterol. 2002;97:2855–2860.
Abstract View: 94 times
PDF Download: 31 times